- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01616888
Paclitaxel Eluting Balloon for SFA In-stent Restenosis
December 5, 2014 updated by: University Health Network, Toronto
Rug Eluting Balloon With Paclitaxel for Treatment of In-stent Restenosis in Femoropopliteal Arteries
The purpose of the study is to evaluate the safety and efficacy on the use of drug eluting balloon (DEB) with paclitaxel to treat in-stent restenosis in femoropopliteal arteries.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Peripheral artery disease (PAD) in the lower extremities can cause claudication, pain in the legs or feet and slowly wounds that can affect patients' quality of life and increase the risk of leg amputation and death.
Both conventional balloon angioplasty (CBA) alone and CBA plus bare metal stents are the current primary endovascular therapy to treat PAD.
However, exaggerated neointimal hyperplasia leading to in-stent restenosis is associated with CBA.
Paclitaxel coated balloons have been recognized to be safe and effective for the treatment of coronary in-stent restenosis, which the investigators hypothesize to be applicable in femoropopliteal cases.
Study Type
Interventional
Enrollment (Anticipated)
30
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2C4
- University Health Network
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 18 years or older
- chronic symptomatic lower limb ischemia defined as Rutherford categories 2, 3, 4 or 5
- in-stent restenosis or occlusion in SFA or PPA 20mm - 200mm
Exclusion Criteria:
- participation in another investigational drug or device trial
- life expectancy less than 12 months
- acute ischemia and/or acute thrombosis of the SFA/PPA
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Treatment arm
SFA angioplasty with In.Pact Admiral drug eluting balloon
|
Angioplasty with drug eluting balloon with paclitaxel on femoropopliteal arteries
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Target lesion patency at 6-month follow-up.
Time Frame: 6-month post index procedure
|
Patency of target lesion at 6-month follow-up based on duplex ultrasound.
|
6-month post index procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical success up to 12 months post index procedure
Time Frame: 12 months post index procedure
|
Improvement on clinical evaluations including staging of PAD according to the Rutherford category, ABI at 1, 6, 12 months post procedure compared to baseline assessment.
|
12 months post index procedure
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2012
Primary Completion (Anticipated)
June 1, 2015
Study Completion (Anticipated)
August 1, 2015
Study Registration Dates
First Submitted
June 7, 2012
First Submitted That Met QC Criteria
June 8, 2012
First Posted (Estimate)
June 12, 2012
Study Record Updates
Last Update Posted (Estimate)
December 9, 2014
Last Update Submitted That Met QC Criteria
December 5, 2014
Last Verified
December 1, 2014
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- KTT2
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on In-stent Arterial Restenosis
-
University Hospital, SaarlandCompletedIn-stent Arterial RestenosisGermany, Brazil
-
Korea University Anam HospitalKorea University Guro Hospital; Yonsei University; Kyungpook National University... and other collaboratorsUnknownIn-stent Arterial RestenosisKorea, Republic of
-
Boston Scientific CorporationActive, not recruiting
-
Klinikum CoburgUnknown
-
Assiut UniversityNot yet recruiting
-
Luzerner KantonsspitalUnknown
-
Fundación Médica para la Investigación y Desarrollo...Abbott Medical Devices; Hospital San Carlos, Madrid; B.Braun Surgical SAUnknown
-
Cordis CorporationCompletedIn-Stent RestenosisUnited States
-
Second Affiliated Hospital, School of Medicine,...West China Hospital; The Third Xiangya Hospital of Central South University; Shanghai... and other collaboratorsUnknownCoronary In-stent RestenosisChina
-
Seoul National University HospitalUnknownIn-stent Restenosis LesionKorea, Republic of
Clinical Trials on PTA with drug eluting balloon with paclitaxel
-
Helsinki University Central HospitalCompletedVascular Access Complication | Restenosis, Vascular Graft | Dialysis Related Complications
-
Academisch Medisch Centrum - Universiteit van Amsterdam...B. Braun Medical B.V.Unknown
-
Helsinki University Central HospitalCompletedPeripheral Artery Occlusive Disease | Peripheral Artery Stenosis | Peripheral Artery RestenosisFinland
-
Zhejiang Zylox Medical Device Co., Ltd.CompletedPeripheral Arterial Disease | Popliteal Artery Stenosis | Popliteal Artery Occlusion | Iliac Artery Occlusion | Femoral Artery Occlusion | Iliac Artery Stenosis | Femoral Artery Stenosis
-
Chinese PLA General HospitalUnknown
-
Shenzhen Salubris Pharmaceuticals Co., Ltd.Changhai HospitalRecruiting
-
Xuzhou Third People's HospitalNot yet recruitingCoronary Artery Disease | Bifurcation Lesion
-
Cook Group IncorporatedWilliam Cook Europe; MED Institute, Incorporated; Cook Japan IncorporatedCompletedPeripheral Vascular DiseasesUnited States, Japan, Germany
-
Groene Hart ZiekenhuisArcher ResearchCompletedVascular Access Complication | Complication of HemodialysisBelgium, Netherlands